Windtree Therapeutics Files 8-K Report
Ticker: WINTW · Form: 8-K · Filed: Apr 17, 2024 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | 8-K |
| Filed Date | Apr 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K, company-update
TL;DR
Windtree Therapeutics filed an 8-K on April 17, 2024, updating on financials.
AI Summary
On April 17, 2024, Windtree Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The company, formerly known as Discovery Laboratories Inc., is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing provides investors with crucial updates on Windtree Therapeutics' financial condition and operational performance, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) and does not contain new material events or significant financial changes.
Key Numbers
- 001-39290 — SEC File Number (Identifies the company's filing with the SEC)
- 94-3171943 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Windtree Therapeutics, Inc. (company) — Registrant
- Discovery Laboratories Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- April 17, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Windtree Therapeutics, Inc.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on April 17, 2024.
What is Windtree Therapeutics, Inc.'s state of incorporation?
Windtree Therapeutics, Inc. is incorporated in Delaware.
What was Windtree Therapeutics, Inc. formerly known as?
Windtree Therapeutics, Inc. was formerly known as Discovery Laboratories Inc. /DE/.
What is the business address of Windtree Therapeutics, Inc.?
The business address of Windtree Therapeutics, Inc. is 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976.
Filing Stats: 568 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-04-17 07:30:44
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share WINT The Nasdaq Capital Ma
Filing Documents
- wint20231117_8k.htm (8-K) — 28KB
- ex_598662.htm (EX-99.1) — 146KB
- logo.jpg (GRAPHIC) — 7KB
- 0001437749-24-012242.txt ( ) — 329KB
- wint-20240417.xsd (EX-101.SCH) — 3KB
- wint-20240417_def.xml (EX-101.DEF) — 11KB
- wint-20240417_lab.xml (EX-101.LAB) — 15KB
- wint-20240417_pre.xml (EX-101.PRE) — 11KB
- wint20231117_8k_htm.xml (XML) — 3KB
02
Item 2.02 Results of Operations and Financial Condition On April 17, 2024, Windtree Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Document 99.1 Press Release of Windtree Therapeutics, Inc., dated April 17, 2024, announcing financial results for the fourth quarter and fiscal year ended December 31, 2023, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Windtree Therapeutics, Inc. By: /s/ Craig E. Fraser Name: Craig E. Fraser Title: President and Chief Executive Officer Date: April 17, 2024